Myriad's BRCA Gene Patents Struck Down In Court; Firm Downplays Impact
This article was originally published in The Gray Sheet
Executive Summary
A federal court ruling invalidating Myriad Genetics' BRCA1 and BRCA2 cancer gene patents will have limited immediate impact on the biotech/diagnostics industry